Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Array BioPharma (ARRY) PT Raised to $23 at Cowen
February 6, 2019 7:56 AM ESTCowen analyst Chris Shibutani raised the price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst commented, "Delivery of another excellent quarter, with F2Q19 MEKTOVI/BRAFTOVI sales of $23MM handily outpacing expectations, bolsters confidence in... More
Array BioPharma (ARRY) PT Raised to $29 at Stifel
February 5, 2019 3:55 PM ESTStifel analyst Stephen Willey raised the price target on Array BioPharma (NASDAQ: ARRY) to $29.00 (from $26.00) while maintaining a Buy rating.
Willey said Q2 confirms the value of the melanoma opportunity.
... MoreArray BioPharma (ARRY) PT Raised to $24 at Jefferies
February 5, 2019 1:47 PM ESTJefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.
Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.
... MoreArray Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat
February 5, 2019 8:02 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.05), $0.10 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $82.5 million versus the consensus estimate of $52.45 million.
Second Quarter of Fiscal 2019 Compared to First Quarter of Fiscal 2019
Net Product Sales for BRAFTOVI + MEKTOVI for the second quarter of fiscal 2019 was $22.7 million, compared to $14.0 million for the first quarter of fiscal 2019.Total Revenue for the second quarter of fiscal 2019 was $82.5 million, compared to $56.9 million for the prior quarter. The increase was primarily due to higher product sales and... More